Halozyme Therapeutics, Inc. Reports Third Quarter 2013 Financial Results
SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter and nine months ended September 30, 2013. Financial highlights for the third quarter include revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share.
Help employers find you! Check out all the jobs and post your resume.